Everence Capital Management’s Anika Therapeutics ANIK Stock Holding History

Everence Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,560	Closed	-$240K	–	713
2022 Q1	$240K	Hold	9,560	–	–	0.02%	634
2021 Q4	$343K	Buy	+9,560	New	+$383K	0.03%	546
2019 Q4	–	Sell	-6,520	Closed	-$358K	–	674
2019 Q3	$358K	Hold	6,520	–	–	0.06%	369
2019 Q2	$265K	Buy	+6,520	New	+$238K	0.04%	458

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Everence Capital Management's ANIK Position: Q2 2022 in Review

Everence Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2022, closing a stake of 9,560 shares — an estimated $240K sold.

Everence Capital Management first reported a position in ANIK in Q2 2019 and held it in 4 quarters. The position peaked at $358K in Q3 2019. 125 funds tracked by Wall St. Rank hold ANIK as of Q2 2022.

Everence Capital Management reported no remaining Anika Therapeutics position as of Q2 2022 after selling out during the quarter.
Everence Capital Management sold 9,560 Anika Therapeutics shares in Q2 2022, an estimated $240K.
Everence Capital Management first reported a position in Anika Therapeutics in Q2 2019 and held it in 4 quarters.
Everence Capital Management's Anika Therapeutics position peaked at $358K in Q3 2019.
125 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2022.

Based on Everence Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.